AngioDynamics(US:ANGO)2021-04-16 18:47Strategic Transformation - AngioDynamics is pursuing larger markets through active portfolio management, relying on technology and innovation to produce measurable patient outcomes[5, 64] - The company is focusing resource development in areas that offer the best opportunities for success[6, 65] - Portfolio transformation and strength are driven by R&D, M&A, and clinical & regulatory efforts, combined with top talent to drive value[7, 66] Peripheral Atherectomy - The US addressable market for peripheral atherectomy is $555 million, with mechanical atherectomy accounting for 77% and laser atherectomy for 23%[19] - AngioDynamics' Auryon system provides access to the peripheral atherectomy market[9] Thrombus Management - The addressable market for right atrium thrombus is $77 million, while the deep vein thrombosis (DVT) market is $1.3 billion and the pulmonary embolism (PE) market is $1.6 billion[28] - AngioVac's use is currently focused on the right atrium, which is a $77 million addressable market[28] - There are an estimated 100,000 to 300,000 VTE-related deaths in the USA annually[25] Irreversible Electroporation (NanoKnife) - In 2020, new cancer cases were estimated at 1,256,970, with breast, lung, and prostate cancer accounting for 22%, 18%, and 15% respectively[48] - Within the U S, 191,930 men will be diagnosed with prostate cancer in 2020[56] Financial Performance (Q3 YTD FY2021) - Revenue was $214.2 million, a 4.1% increase year-over-year (YOY) compared to $205.8 million[61] - Adjusted EBITDA was $15.0 million, a decrease of $2.5 million compared to $17.5 million[61] - Free cash flow was $7.3 million, an increase of $31.5 million compared to ($24.2) million[61]